Recce Pharmaceuticals Ltd (RCE:ASX)

$1.14

right-arrow Created with Sketch. -0.015 (-1.3%)
MCAP $198.1M
Last trade 15.42pm 10/05/2021 20mins delayed

Latest Announcements

04/05/2021 Price SensitivePSRCERecce Pharmaceuticals Ltd
27/04/2021 Price SensitivePSRCERecce Pharmaceuticals Ltd
15/04/2021 Price SensitivePSRCERecce Pharmaceuticals Ltd
07/04/2021 Price SensitivePSRCERecce Pharmaceuticals Ltd
01/04/2021 Price SensitivePSRCERecce Pharmaceuticals Ltd
30/03/2021 Price SensitivePSRCERecce Pharmaceuticals Ltd
15/03/2021RCERecce Pharmaceuticals Ltd
12/03/2021 Price SensitivePSRCERecce Pharmaceuticals Ltd

Company Overview

Recce Pharmaceuticals Ltd, formerly Recce Limited, is an Australia-based research-based pharmaceutical company. The Company is principally engaged in research and development of antibiotic drugs and anticancer drugs. The Company's antibiotics kill both susceptible bacteria and drug resistant super bugs throughout the world health danger arising from resistance to present-day antibiotics. The Company offers antibiotic drugs to treat the diseases caused by Sepsis, Helicobacter Pylori (H.Pylori), Escherichia coli (E.coli), Gonorrhea and Tuberculosis (TB). The Company offers anticancer drugs to treat various cancers, such as leukemia, prostate, lung, stomach, intestine, kidney and melanoma. The Company also offers polymer-antibiotics targeted for human use. The Company's Recce antibiotic kills all types of bacteria, including superbugs. Its subsidiaries include Recce (USA) LLP and Recce (UK) Limited.

RCE in the news

Search Previous Announcements